Get more info on this report!The World Market for Diabetes TreatmentsOctober 1, 2010This Kalorama Information report , The World Market for Diabetes Treatments, providesmarket estimates and forecasts for the world market for diabetes treatments. Thediabetes market is one of the fastest growing markets within the pharmaceutical sector,and is one of the few pharmaceutical sectors that are likely to continue to grow atdouble digit rates throughout the forecast period. Major contributing factors to growthare increasing obesity and an aging worldwide population. The total market for diabetestreatments is divided into two major segments: Insulin Markets in US, Europe, Japan, ROW Oral Hypoglycemics in US, Europe, Japan, ROWFor each of these market segments the report provides market share and regionalbreakout (US, Europe, Asia, ROW). The report also discusses treatment for diabetescomplications and natural and herbal treatments.The report’s geographic scope is worldwide with information for specific geographicalregions; world demographics; life expectancy by country, and other general issuesaffecting the market. Trends covered in the report include: New Products and the Development Pipeline (Afrezza, Bydureon, Syncria, AVE0010, Balaglitazone, Metgluna Otelixizumab and others) Transplantation Research Efforts Β-Cell Transplantation Research Potential New Drug for Type 2 Diabetes Insulin Pills Three-month Insulin Shot Outsourcing of Diabetes Projects Reclassification of Cause of DeathInformation is presented as a worldwide overview, with special emphasis on the U.S.,Europe, and other key markets.
A market summary includes market analysis by product and region and a competitiveanalysis of leading providers. Additionally, key company profiles are included, includingprofiles of the following: Amylin Pharmaceuticals AstraZeneca GlaxoSmithKline Eli Lilly & Co. Merck Metabolex, Inc. Novo Nordisk A/S Pfizer Inc. Sanofi-Aventis Group Takeda Pharmaceutical Company LimitedThe information for this report was gathered using both primary and secondary researchincluding comprehensive research of secondary sources such as company literature,databases, investment reports, and medical and business journals. Telephoneinterviews and email correspondence were the primary method of gathering information.For the purpose of this study, Kalorama Information conducted interviews with morethan 25 key industry officials, consultants, health care providers, and governmentpersonnel. These sources were the primary basis in gathering information specificallyrelating to revenue and market share data presented in this report. Additional interviewswere completed with relevant company representatives including marketing directors,division managers, and product representatives.All market data pertains to the world market at the manufacturers’ level. The base yearfor data was 2009. Historical data was provided for the years 2008, with forecast dataprovided for 2010 through 2015. Compound annual growth rates (CAGRs) are providedfor 2008-2015 periods for each region and/or segment covered. Competitive analysis isprovided for the year 2009. The forecasted market analysis for 2009-2015 was largelybased on demographic trends, new developments, innovative technology and globalexpansion.Table of ContentsCHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and Trends Affecting Market Leading Competitors
CHAPTER TWO: INTRODUCTION Background Therapeutic Practices France Germany Italy Japan Spain United Kingdom United States China IndiaCHAPTER THREE: CURRENT THERAPEUTICS FOR DIABETES Insulin o Regular Insulin o Long-Acting and Basal Insulin o Rapidly Acting Insulin o Combinations o Insulin Pumps o Insulin Pens o Inhaled Insulin o Other Treatments Oral Hypoglycemics Sulfonylureas o Biguanides o á-Glucosidase Inhibitors o Thiazolidinediones o Meglitinides o D-Phenylalanine Derivatives o GLP1 Agonists o DPP-IV Inhibitor Current Therapeutics for Diabetic Complications o Antihypertensive Therapy o ACE Inhibitors o á/â(Alpha/Beta)-Blockers o Calcium Channel Blockers o Diuretics o Angiotensin II Receptor Antagonists Dyslipidemia Therapy HMG-CoA Reductase Inhibitors--Statins Bile Acid Sequestrants
Fibric Acid Derivatives Niacin Cholesterol Absorption Inhibitors Atherosclerosis Therapy Arrhythmia Therapy Peripheral Vascular Disease TherapyCHAPTER THREE: TOTAL MARKET REVENUES, FORECAST AND COMPETITIVEANALYSIS Total Worldwide Diabetes Market Analysis by Geographic Segment Total Worldwide Diabetes Market Competitive Analysis Total Worldwide Diabetes Market by Segment Insulin Oral HypoglycemicsCHAPTER FOUR: KEY ISSUES, TRENDS AND DEVELOPMENTS New Products and the Development Pipeline o Afrezza o Bydureon o Syncria o AVE0010 Once Daily and Twice Daily o Balaglitazone o Dapagliflozin and Dapagliflozin/Meformin Fixed Dose Combination o Degludec and Degludec Plus o Daimyd Vaccine o Dutogliptin o Glinsuma, Glufast, Metgluna o MK 0431C o Ondero o Oral-lyn o Otelixizumab o Taspoglutide Transplantation Research Efforts o Â-Cell Transplantation Research Potential New Drug for Type 2 Diabetes Insulin Pills Three-month Insulin Shot Outsourcing of Diabetes Projects Reclassification of Cause of DeathCHAPTER FIVE: NUTRITIONAL SUPPLEMENT AND HERBAL APPROACHES TOTHE TREATMENT OF DIABETES Background
Nutritional Supplements o Ascorbic Acid (Vitamin C) o Biotin o Chromium o Copper o Magnesium o Niacin and Niacinamide o Potassium o Selenium o Thiamine o Vanadium o Vitamin B6 (Pyridoxine) o Vitamin B12 o Vitamin E o Zinc Nutritional Treatment of Diabetic Neuropathy o Herbal Treatment of Diabetes Aloe (Various) Arctium lappa (Burdock Root) Allium cepa (Onion) Grifola frondosa (Maitake Mushroom) Mulberry Panax ginseng (Korean ginseng) o Ayurvedic Medicine and Herbs Gymnema sylvestre (Asclepias germinata) Momordica charantia (Bitter Gourd) Trigonella foenum graecum (Fenugreek) o Other Herbs with Significant Anti-Diabetic Effects o Traditional Chinese MedicineCHAPTER SIX: CONCLUSIONS AND STRATEGIC IMPLICATIONS First Conclusion o Implications: Second Conclusion o Implications: Third Conclusion o Implications: Fourth Conclusion o Implications: Fifth Conclusion o Implications: Sixth Conclusion o Implications: Seventh Conclusion o Implications:
Eighth Conclusion o Implications: Ninth Conclusion o Implications: Tenth Conclusion o Implications: Eleventh Conclusion o Implications: Twelfth Conclusion o Implications: Thirteenth Conclusion o Implications: Fourteenth Conclusion o Implications: Fifteenth Conclusion o Implications:CHAPTER SEVEN: LEADING MANUFACTURERS Overview Amylin Pharmaceuticals AstraZeneca GlaxoSmithKline Eli Lilly & Co. Merck Metabolex, Inc. Novo Nordisk A/S Pfizer Inc. Sanofi-Aventis Group Takeda Pharmaceutical Company LimitedAvailable immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=2809047US: 800.298.5699
UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004